Eun Yang
Stock Analyst
(n/a)
# 4,647
Out of 4,655 analysts
50
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $374.02 | +15.50% | 8 | Sep 23, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: Hold | $65 → $2 | $2.79 | -28.32% | 3 | Jun 17, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $1.53 | +422.88% | 2 | May 14, 2024 | |
| ATXS Astria Therapeutics | Maintains: Buy | $22 → $27 | $11.32 | +138.52% | 2 | Mar 25, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $1.01 | +48.51% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $25.48 | +29.51% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $9.04 | +209.73% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $27.63 | -2.28% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $3.63 | +92.84% | 1 | Feb 10, 2023 | |
| CVAC CureVac | Upgrades: Buy | n/a | $2.76 | - | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $17 → $7 | $4.37 | +60.18% | 3 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $4.03 | +520.35% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $75 | $1.54 | +4,770.13% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $84 | $90.70 | -7.39% | 3 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.76 | +564.89% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $5.93 | - | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $15.67 | +123.36% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $319.22 | -31.08% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $38 → $31 | $16.40 | +89.02% | 5 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $4.00 | +9,900.00% | 1 | Jul 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $173.79 | +78.38% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $89.51 | -10.62% | 3 | Jul 11, 2017 |
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $374.02
Upside: +15.50%
Aerovate Therapeutics
Jun 17, 2024
Downgrades: Hold
Price Target: $65 → $2
Current: $2.79
Upside: -28.32%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $1.53
Upside: +422.88%
Astria Therapeutics
Mar 25, 2024
Maintains: Buy
Price Target: $22 → $27
Current: $11.32
Upside: +138.52%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $1.01
Upside: +48.51%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $25.48
Upside: +29.51%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $9.04
Upside: +209.73%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $27.63
Upside: -2.28%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $3.63
Upside: +92.84%
CureVac
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $2.76
Upside: -
Dec 8, 2022
Downgrades: Hold
Price Target: $17 → $7
Current: $4.37
Upside: +60.18%
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $4.03
Upside: +520.35%
Sep 22, 2022
Maintains: Buy
Price Target: $525 → $75
Current: $1.54
Upside: +4,770.13%
Aug 22, 2022
Maintains: Buy
Price Target: $78 → $84
Current: $90.70
Upside: -7.39%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $3.76
Upside: +564.89%
Jul 12, 2021
Initiates: Buy
Price Target: n/a
Current: $5.93
Upside: -
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $15.67
Upside: +123.36%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $319.22
Upside: -31.08%
Nov 3, 2017
Maintains: Hold
Price Target: $38 → $31
Current: $16.40
Upside: +89.02%
Jul 24, 2017
Initiates: Buy
Price Target: $400
Current: $4.00
Upside: +9,900.00%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $173.79
Upside: +78.38%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $89.51
Upside: -10.62%